Check out our review article describing recent updates in LAG3 biology and therapeutics in @TrendsinPharma with @jwang133 and @Curie_Bio colleagues: authors.elsevier.com/c/1lFgx…
Proud to have our work with @CarolynBertozzi
and Ron Levy on tumor-targeted cancer therapeutics featured in the @StanfordOTL annual report tinyurl.com/pawxhfhx; now being developed at TwoStep Therapeutics, led by lab alum Caitlyn Miller @CaitlynBioE
Congrats to lab alum Bob Chen and the @OmniAbTech team on winning "Best in Show" at @PEGSboston for their innovative and impactful xPloration B cell/ Ab screening platform.
🏆 Congratulations to @OmniAbTech , Inc. — winner of the Best of Show Award at #PEGSummit 2025!
Their xPloration® Partner Access Program captured attendee votes by a landslide for its innovation and impact.
Thanks to all who participated, and congrats again to the OmniAb team!
Congrats to lab alum Bob Chen and the OmniAb team for their Best in Show award at PEGSummit for the xPloration® B cell protein/Ab engineering screening cell platform!
Excited to see our lab's B cell screening technology, spearheaded by Cochran alum and xCella Biosciences co-founder Bob Chen, rolled out as a now commercial instrument from antibody discovery company @OmniAbTech.
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit
investors.omniab.com/investo…
CochranLab retweeted
Congratulations to Professor Jennifer Cochran @CochranLab who was recently elected to the National Academy of Engineering @theNAEng for protein discovery and development, biotechnology entrepreneurship, and leadership in academic bioengineering!
news.stanford.edu/stories/20…
CochranLab retweeted
I'm excited to share our work "Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function" that's now out in PNAS! 1/3
Link to paper: pnas.org/doi/10.1073/pnas.23…
Link to press release: news.stanford.edu/2024/03/11…
CochranLab retweeted
#JI_TopRead from @CaitlynBioE @CochranLab @CarolynBertozzi @StanfordHealth | #TLR9 agonist, PIP-CpG, enhances the CD8 #Tcell response to spontaneous tumors | #ReadTheJI #immunology #AuthorChoice #FreetoRead #TumorImmunology
👉 ow.ly/FTbV50P6FNv
CochranLab retweeted
In the physiologically relevant MMTV-PyMT GEMM model, @CaitlynBioE @BarfiIdit @CarolynBertozzi demonstrated that systemic delivery of a tumor integrin-targeted TLR9 agonist (PIP-CpG) led to sustained elimination [...] bit.ly/3Cu9QTC
CochranLab retweeted
Thrilled to announce that our new PIP-CpG paper is now live @J_Immunol . PIP-CpG is a tumor-targeting immunotherapy that is in preclinical development & we are hoping to advance it to the clinic in the coming years. doi.org/10.4049/jimmunol.220… .
A 🧵👇(1/13)
Congrats to joint @StanfordBioE PhD student @hollander_mj, @CarolynBertozzi and team for this exciting collaborative work!
This quoted post is unavailable.